Therefore, additional pharmacological inhibition of SGLT1 might have significant clinical implications on top of SGLT2 blockade in high-risk type 2 diabetic patients, which have not been established yet. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.